India remains on USTR list of IP problem countries

4 May 2020
office-of-the-us-trade-representative-big

India continues to be on the 'Priority Watch List' of the US Trade Representative (USTR) for lack of sufficient measurable improvements to its Intellectual Property framework. Despite making "meaningful progress" to enhance IP protection and enforcement in some areas, India did not resolve recent and long-standing challenges, and created new ones.

Long-standing IP challenges facing US businesses in India include those which make it difficult for innovators to receive, maintain, and enforce patents in India, particularly for pharmaceuticals; ineffectual enforcement activities, copyright policies that fail to incentivize the creation and commercialization of content, and an outdated and insufficient trade secrets legal framework, the USTR said in its report.

The US placed 10 countries, including some of its major trading partners like India and China, on the list, alleging that enforcement of IPR has deteriorated or remained at inadequate levels and the Americans who rely on their protection have difficulty with fair and equitable market access.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Generics